No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 32,893 | 37,296 | 35,382 | 30,446 | 36,288 | 36,799 | 36,799 | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 2,959 | 5,364 | 2,280 | 1,845 | 2,891 | 3,058 | 3,058 | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Stella Chemifa Corporation, a Japanese company established in 1916 and headquartered in Osaka, specializes as a global manufacturer and supplier of inorganic fluorine compounds. Formerly known as Hashimoto Chemical Corporation until its rebranding in 1997, the company offers a comprehensive product portfolio tailored for diverse industrial applications worldwide. For the electronics sector, Stella Chemifa provides essential materials such as hydrofluoric acid, buffered hydrofluoric acid, and various etching solutions used in the production of semiconductors, liquid crystal displays, and solar cells. It also supplies a range of metal fluorides, including calcium, aluminum, and lithium fluoride, crucial for optical applications, alongside lithium hexafluorophosphate for battery manufacturing. Its offerings extend to numerous boron trifluoride compounds, serving as vital reactive catalysts across different chemical processes. Additionally, the company produces anhydrous hydrofluoric acid and 55% hydrofluoric acid, utilized in surface treatment and as more environmentally conscious alternatives to CFCs. Stella Chemifa also supports the nuclear energy industry with potassium fluoroborate and boric acid, and provides tin fluoride (II) USP for products requiring GMP compliance. Beyond these specialized compounds, the company's extensive catalog includes a broad array of other fluorochemicals, such as fluorosilicic acid, various fluorosilicates, fluoroboric acid, diverse fluoroborates, and a selection of ammonium, sodium, and potassium fluorides. Complementing its manufacturing operations, Stella Chemifa offers logistics services for the transportation of specialized chemical substances, high-pressure gases, and hazardous materials. Demonstrating a commitment to innovation, the company is also actively involved in the development of Boron Neutron Capture therapy for cancer treatment.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Stella Chemifa Corporation (4109.T)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Stella Chemifa Corporation, a Japanese company established in 1916 and headquartered in Osaka, specializes as a global manufacturer and supplier of inorganic fluorine compounds. Formerly known as Hashimoto Chemical Corporation until its rebranding in 1997, the company offers a comprehensive product portfolio tailored for diverse industrial applications worldwide. For the electronics sector, Stella Chemifa provides essential materials such as hydrofluoric acid, buffered hydrofluoric acid, and various etching solutions used in the production of semiconductors, liquid crystal displays, and solar cells. It also supplies a range of metal fluorides, including calcium, aluminum, and lithium fluoride, crucial for optical applications, alongside lithium hexafluorophosphate for battery manufacturing. Its offerings extend to numerous boron trifluoride compounds, serving as vital reactive catalysts across different chemical processes. Additionally, the company produces anhydrous hydrofluoric acid and 55% hydrofluoric acid, utilized in surface treatment and as more environmentally conscious alternatives to CFCs. Stella Chemifa also supports the nuclear energy industry with potassium fluoroborate and boric acid, and provides tin fluoride (II) USP for products requiring GMP compliance. Beyond these specialized compounds, the company's extensive catalog includes a broad array of other fluorochemicals, such as fluorosilicic acid, various fluorosilicates, fluoroboric acid, diverse fluoroborates, and a selection of ammonium, sodium, and potassium fluorides. Complementing its manufacturing operations, Stella Chemifa offers logistics services for the transportation of specialized chemical substances, high-pressure gases, and hazardous materials. Demonstrating a commitment to innovation, the company is also actively involved in the development of Boron Neutron Capture therapy for cancer treatment.
